Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), headquartered in Marlborough, Massachusetts, is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company's proprietary INTASYL™ siRNA gene silencing technology is at the forefront of its efforts to enhance the effectiveness of immune cells in targeting and destroying tumor cells.
Phio's core product pipeline includes:
- PH-762: Targets the checkpoint protein PD-1 on immune cells, enhancing their ability to attack tumors. Currently in Phase 1b clinical trials, PH-762 is being tested for its efficacy in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
- PH-804: Focuses on the suppressive immune receptor TIGIT, present on T cells and natural killer cells, to bolster immune responses against cancer.
- PH-790: Aims to silence the PD-L1 protein, which normally prevents immune cells from attacking non-harmful cells, thereby boosting the body's natural defenses against cancer.
Phio Pharmaceuticals collaborates with leading institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München to advance their research and development efforts. The company's financial health, as of the latest reports, shows a cash position of $6.5 million, with a significant reduction in research and development expenses aimed at transitioning from discovery to product development.
Phio's latest updates include the presentation of new data on PH-762 at various scientific conferences and the initiation of new partnerships. These efforts underscore Phio's commitment to delivering cutting-edge cancer treatments and improving patient outcomes.
For more details, visit the company's website at www.phiopharma.com.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces the upcoming presentation of new data on its lead clinical product candidate, PH-762, at the Annual Meeting of the Society of Clinical Oncology (ASCO). PH-762, an INTASYL compound, is being studied in a US clinical trial for specific skin cancers. The open-label Phase 1b clinical study aims to assess safety and efficacy in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The data will be presented by Dr. Mary Spellman at ASCO in Chicago, Illinois on June 1, 2024.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What does Phio Pharmaceuticals Corp. do?
What is INTASYL™ technology?
What are Phio's key products?
Who are Phio's collaboration partners?
What recent achievements has Phio Pharmaceuticals announced?
What is the financial condition of Phio Pharmaceuticals?
What is PH-762?
What cancers is PH-762 being tested for?
What is the significance of INTASYL™ technology?
Where can I find more information about Phio Pharmaceuticals?
